Showing 3571-3580 of 19355 results for "".
Tailoring Treatment: Can You Select the Best Therapy?
https://reachmd.com/programs/cme/tailoring-treatment-can-you-select-the-best-therapy/51483/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
https://reachmd.com/clinical-practice/cardiology/advancing-care-for-women-with-aortic-stenosis-2-year-outcomes-for-women-in-the-5-year-smart-trial/39669/Two-year SMART data show differences in valve performance and hemodynamics that may inform your treatment of women with AS and small annuli.Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
https://reachmd.com/programs/cme/expert-perspectives-from-aua-2025-contextualizing-the-evolving-landscape-of-bladder-cancer/33076/Explore expert insights from AUA 2025 on advancing bladder cancer care, with updates on NMIBC treatment and biomarker-driven strategies.Targeting CKD-aP at the Source: Key Mechanisms and Treatments
https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/Explore CKD-associated pruritus mechanisms, clinical impact, and evidence-based treatments, including kappa-opioid receptor agonists.Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
https://reachmd.com/clinical-practice/oncology-hematology/adjuvant-pembrolizumab-plus-cisplatin-based-chemoradiation-in-locally-advanced-hnscc-first-results-from-the-randomized-phase-2b-adrisk-trial/39706/In the phase 2b ADRISK study, pembrolizumab added to adjuvant cisplatin-based chemoradiation did not significantly improve EFS or OS in locally advanced HNSCC.Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/distinguishing-first-line-treatment-adverse-event-profiles-in-her2-negative-upper-gi-cancers/37691/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingDriving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond
https://reachmd.com/programs/cme/driving-progress-in-cardiology-exploring-the-role-of-fxi-in-acute-coronary-syndromes-beyond/32980/Don’t miss this broadcast replay on the potential role of factor XI inhibition in acute coronary syndrome, Afib, and secondary stroke prevention.Why CELMoDs Matter in Myeloma
https://reachmd.com/programs/cme/why-celmods-matter-in-myeloma/36558/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityStrategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
https://reachmd.com/programs/cme/strategic-excellence-mastering-the-expanding-attr-cm-therapeutic-landscape-in-pharmacy-practice/18124/Enhance pharmacists' expertise in managing ATTR-CM with advanced knowledge and clinical insights for this evolving landscape.Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
https://reachmd.com/programs/cme/transforming-care-in-pediatric-patients-with-c3-glomerulopathy-targeting-c3-at-the-source/54143/Join Drs. Daga and Lafayette for a case discussion exploring the optimal use of complement inhibitor therapy in a pediatric patient with C3 glomerulopathy.